

# Roger J Packer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2114103/publications.pdf>

Version: 2024-02-01

314  
papers

30,232  
citations

2795

94  
h-index

5364

164  
g-index

325  
all docs

325  
docs citations

325  
times ranked

15726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	0.6	9
2	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	0.6	9
3	Two clinically distinct cases of infant hemispheric glioma carrying <i>ZCCHC8:ROS1</i> fusion and responding to entrectinib. <i>Neuro-Oncology</i> , 2022, 24, 1029-1031.	0.6	4
4	Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, , .	0.6	1
5	Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors. <i>Endocrine Reviews</i> , 2022, 43, 794-823.	8.9	20
6	Characteristics of children ≤36 months of age with DIPG: A report from the international DIPG registry. <i>Neuro-Oncology</i> , 2022, 24, 2190-2199.	0.6	4
7	OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO). <i>Neuro-Oncology</i> , 2022, 24, i148-i148.	0.6	2
8	DIPG-48. MRI volumetric and machine learning based analyses predict survival outcome in pediatric diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i29-i29.	0.6	0
9	IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. <i>Neuro-Oncology</i> , 2022, 24, i85-i86.	0.6	1
10	IMG-08. Response assessment for pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Neuro-Oncology</i> , 2022, 24, i78-i78.	0.6	0
11	DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i29-i29.	0.6	0
12	Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. <i>Nature Reviews Neurology</i> , 2022, 18, 515-529.	4.9	100
13	Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) <i>BRAF</i> V600 mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2009-2009.	0.8	9
14	Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	1
15	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600 mutant pediatric low-grade glioma (pLGG).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA2002-LBA2002.	0.8	35
16	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28833.	0.8	9
17	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	15.2	46
18	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40

#	ARTICLE	IF	CITATIONS
19	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	0.8	54
20	The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. <i>Neuro-Oncology</i> , 2021, 23, 1215-1217.	0.6	106
21	Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29172.	0.8	3
22	EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS. <i>Neuro-Oncology</i> , 2021, 23, i5-i6.	0.6	0
23	Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. <i>Neurology: Genetics</i> , 2021, 7, e616.	0.9	14
24	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2685-2697.	0.8	91
25	Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors. <i>Developmental Cell</i> , 2021, 56, 2871-2885.e6.	3.1	14
26	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	3.9	34
27	Computerized Working Memory Training for Children With Neurofibromatosis Type 1 (NF1): A Pilot Study. <i>Journal of Child Neurology</i> , 2021, 36, 088307382110380.	0.7	2
28	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. <i>JAMA Oncology</i> , 2021, 7, 1313.	3.4	61
29	The experience of successful treatment of <i>ETV6-NTRK3</i> -positive infant glioblastoma with entrectinib. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab022.	0.4	7
30	NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES. <i>Neuro-Oncology</i> , 2021, 23, vi129-vi130.	0.6	0
31	A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 437-445.	1.4	5
32	Integrated analysis of pediatric low-grade glioma: clinical implications and the path forward. <i>Neuro-Oncology</i> , 2020, 22, 1413-1414.	0.6	1
33	Pediatric diffuse leptomeningeal glioneuronal tumor: Two clinical cases of successful targeted therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28478.	0.8	7
34	JNO special issue: an update on pediatric neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2020, 150, 1-4.	1.4	1
35	New treatment modalities in NF-related neuroglial tumors. <i>Child's Nervous System</i> , 2020, 36, 2377-2384.	0.6	6
36	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	1.5	62

#	ARTICLE	IF	CITATIONS
37	Update on Pediatric Brain Tumors: the Molecular Era and Neuro-immunologic Beginnings. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 30.	2.0	9
38	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , The, 2020, 21, e305-e316.	5.1	115
39	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	0.6	51
40	Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. <i>Journal of Child Neurology</i> , 2020, 35, 791-798.	0.7	11
41	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020, 10, 10954.	1.6	7
42	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	0.6	44
43	Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 245-249.	1.7	9
44	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. <i>Pediatric Neurology</i> , 2020, 107, 7-15.	1.0	2
45	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€œSupported Network for Excellence in Neuroscience Clinical Trials. <i>JAMA Neurology</i> , 2020, 77, 755.	4.5	6
46	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1â€œassociated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	0.6	45
47	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
48	MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii391-iii391.	0.6	2
49	MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDRENâ€™S ONCOLOGY GROUP (COG) ACNS0331. <i>Neuro-Oncology</i> , 2020, 22, iii391-iii391.	0.6	0
50	LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES. <i>Neuro-Oncology</i> , 2020, 22, iii371-iii371.	0.6	0
51	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. <i>Neuro-Oncology</i> , 2020, 22, iii332-iii332.	0.6	0
52	Unsupervised MRI Homogenization: Application to Pediatric Anterior Visual Pathway Segmentation. <i>Lecture Notes in Computer Science</i> , 2020, 12436, 180-188.	1.0	6
53	CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104). <i>Neuro-Oncology</i> , 2020, 22, ii43-ii43.	0.6	0
54	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	0.8	73

#	ARTICLE	IF	CITATIONS
55	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1011-1022.	5.1	315
56	Autism-associated Nf1 deficiency disrupts corticocortical and corticostriatal functional connectivity in human and mouse. <i>Neurobiology of Disease</i> , 2019, 130, 104479.	2.1	36
57	LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. <i>Neuro-Oncology</i> , 2019, 21, ii98-ii99.	0.6	3
58	<i>MYC</i> Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells. <i>Cancer Research</i> , 2019, 79, 1967-1980.	0.4	29
59	Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 731-740.	0.8	79
60	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1796-1803.	1.2	11
61	Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. <i>Neuro-Oncology</i> , 2018, 20, 132-142.	0.6	42
62	Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26917.	0.8	15
63	Optic pathway "hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. <i>Journal of Neurosurgery</i> , 2018, 129, 1407-1415.	0.9	14
64	Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee". <i>Neuro-Oncology</i> , 2018, 20, 144-145.	0.6	4
65	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	0.6	74
66	Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26838.	0.8	27
67	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	0.6	116
68	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
69	DIPG-53. COMPREHENSIVE CLINICAL AND MOLECULAR ANALYSIS OF PEDIATRIC THALAMIC GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i59-i60.	0.6	0
70	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395.	0.8	58
71	CRAN-16. IMPORTANCE OF SURGICAL INTERVENTION IN RECOVERY OF VISUAL FUNCTION IN A TEENAGER WITH AN ACIDOPHILIC STEM CELL ADENOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i40.	0.6	0
72	PDTM-13. OVEREXPRESSION OF MYC ALONE IS SUFFICIENT TO INITIATE GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi206-vi206.	0.6	0

#	ARTICLE	IF	CITATIONS
73	PDTM-15. IDENTIFICATION AND CHARACTERIZATION OF WILMSâ€™ TUMOR PROTEIN IN PEDIATRIC MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi206-vi207.	0.6	0
74	Liquid biopsy for pediatric central nervous system tumors. <i>Npj Precision Oncology</i> , 2018, 2, 29.	2.3	24
75	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143.	0.6	14
76	DIPG-69. CHARACTERISTICS OF PATIENTS â‰¥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	0.6	1
77	NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY. <i>Neuro-Oncology</i> , 2018, 20, i142-i142.	0.6	3
78	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP ACNS0332 TRIAL. <i>Neuro-Oncology</i> , 2018, 20, i68-i69.	0.6	0
79	DIPG-51. BLACKFYNN: A SECURE, CLOUD-BASED PLATFORM FOR SHARING AND ANALYZING RESEARCH READY DATA FOR PEDIATRIC CNS CANCERS. <i>Neuro-Oncology</i> , 2018, 20, i59-i59.	0.6	1
80	Chemotherapy for Medulloblastomaâ€™ Childhood. , 2018, , 569-583.		0
81	Pediatric Brain Tumors. <i>Neurologic Clinics</i> , 2018, 36, 533-556.	0.8	163
82	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN <3 YEARS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	0.6	0
83	Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. <i>Neuro-Oncology</i> , 2017, 19, now242.	0.6	63
84	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
85	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
86	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	9.4	112
87	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. <i>Journal of Neuro-Oncology</i> , 2017, 133, 119-128.	1.4	32
88	Computerized cognitive training for children with neurofibromatosis type 1: A pilot resting-state fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2017, 266, 53-58.	0.9	16
89	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. <i>Neuro-Oncology</i> , 2017, 19, 1135-1144.	0.6	236
90	A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. <i>Neurology</i> , 2017, 88, 1584-1589.	1.5	53

#	ARTICLE	IF	CITATIONS
91	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. <i>Neuro-Oncology</i> , 2017, 19, 1279-1280.	0.6	93
92	<i>Pediatric Neuro-oncology.</i> , 2017, , 957-962.		1
93	Case-based review: pediatric medulloblastoma. <i>Neuro-Oncology Practice</i> , 2017, 4, 138-150.	1.0	22
94	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	0.8	232
95	High Incidence of Venous Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (COG P99702). <i>Pediatric Blood and Cancer</i> , 2016, 63, 1563-1570.	0.8	13
96	Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 547-550.	0.8	1
97	Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. <i>Cancer</i> , 2016, 122, 1928-1936.	2.0	90
98	MB-109PRELIMINARY RESULTS OF COG ACNS0331: A PHASE III TRIAL OF INVOLVED FIELD RADIOTHERAPY (IFRT) AND LOW DOSE CRANIOSPINAL IRRADIATION (LD-CSI) WITH CHEMOTHERAPY IN AVERAGE RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2016, 18, iii122-iii122.	0.6	20
99	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	3.9	478
100	Quantitative MRI criteria for optic pathway enlargement in neurofibromatosis type 1. <i>Neurology</i> , 2016, 86, 2264-2270.	1.5	21
101	Pilocytic astrocytomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 329-344.	1.0	52
102	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	0.8	94
103	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. <i>Neurology</i> , 2016, 87, 2575-2584.	1.5	76
104	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. <i>Nature Communications</i> , 2016, 7, 11185.	5.8	197
105	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
106	A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 443-451.	1.4	69
107	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	13.7	266
108	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274

#	ARTICLE	IF	CITATIONS
109	The impact of molecular analysis on the survival of children with embryonal tumors. <i>Translational Pediatrics</i> , 2016, 5, 5-8.	0.5	3
110	Cingulate Apparent Diffusion Coefficient measurements in children with Neurofibromatosis type 1. <i>Journal of Pediatric Neuroradiology</i> , 2015, 03, 121-126.	0.1	0
111	A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study. <i>Neuro-Oncology</i> , 2015, 17, 1132-1138.	0.6	33
112	SHH inhibitors for the treatment of medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 763-770.	1.4	39
113	Medulloblastoma: Toward Biologically Based Management. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 6-13.	1.0	20
114	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2015, 17, 596-603.	0.6	118
115	Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. <i>Journal of Neuro-Oncology</i> , 2015, 121, 217-224.	1.4	20
116	Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. <i>Journal of Neuro-Oncology</i> , 2015, 121, 573-581.	1.4	30
117	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	0.8	368
118	Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. <i>Pediatric Neurology</i> , 2015, 53, 31-46.	1.0	125
119	Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 776-783.	0.8	58
120	A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. <i>Acta Neuropathologica</i> , 2015, 130, 575-585.	3.9	50
121	Proteomic profiling of high risk medulloblastoma reveals functional biology. <i>Oncotarget</i> , 2015, 6, 14584-14595.	0.8	20
122	Handheld Optical Coherence Tomography During Sedation in Young Children With Optic Pathway Gliomas. <i>JAMA Ophthalmology</i> , 2014, 132, 265.	1.4	57
123	Marked Recovery of Vision in Children With Optic Pathway Gliomas Treated With Bevacizumab. <i>JAMA Ophthalmology</i> , 2014, 132, 111.	1.4	100
124	Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: Report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 102-106.	0.8	42
125	Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. <i>Child's Nervous System</i> , 2014, 30, 979-990.	0.6	41
126	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2014, 16, 1554-1559.	0.6	44



#	ARTICLE	IF	CITATIONS
127	Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas: a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2014, 16, 310-317.	0.6	132
128	Parental and physician attitudes toward medulloblastoma treatment. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1149-1150.	0.8	0
129	Advances in the Management of Low-Grade Gliomas. <i>Current Oncology Reports</i> , 2014, 16, 398.	1.8	36
130	A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10065-10065.	0.8	10
131	Health and functional status of long-term adult medulloblastoma/PNet survivors: A report from the Childhood Cancer Survivor Study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9515-9515.	0.8	1
132	A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). <i>Pediatric Blood and Cancer</i> , 2013, 60, 71-76.	0.8	52
133	A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. <i>Journal of Neuro-Oncology</i> , 2013, 114, 173-179.	1.4	55
134	Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1397-1401.	0.8	64
135	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	5.1	307
136	Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2013, 19, 6305-6312.	3.2	180
137	Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. <i>Neuro-Oncology</i> , 2013, 15, 97-103.	0.6	212
138	Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). <i>Current Treatment Options in Neurology</i> , 2013, 15, 593-606.	0.7	47
139	Children's Oncology Group's 2013 blueprint for research: Central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1022-1026.	0.8	74
140	Radiation, Atherosclerotic Risk Factors, and Stroke Risk in Survivors of Pediatric Cancer: A Report From the Childhood Cancer Survivor Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 649-655.	0.4	124
141	Visual Outcomes in Children With Neurofibromatosis Type 1 and Orbitotemporal Plexiform Neurofibromas. <i>American Journal of Ophthalmology</i> , 2013, 155, 1089-1094.e1.	1.7	27
142	Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1350-1357.	0.8	84
143	Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. <i>Pediatric Blood and Cancer</i> , 2013, 60, 776-782.	0.8	114
144	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8188-8193.	3.3	188

#	ARTICLE	IF	CITATIONS
145	A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. Journal of Clinical Oncology, 2013, 31, 2035-2035.	0.8	8
146	Event-Free Survival of Children with Average-Risk Medulloblastoma: Treatment with Craniospinal Radiation Followed by Adjuvant Chemotherapy. Pediatric Cancer, 2013, , 93-101.	0.0	0
147	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-Oncology, 2012, 14, 790-797.	0.6	248
148	Understanding the molecular complexity of medulloblastoma. Nature Reviews Neurology, 2012, 8, 539-540.	4.9	6
149	Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials. Frontiers in Oncology, 2012, 2, 185.	1.3	13
150	Biologically Targeted Therapeutics in Pediatric Brain Tumors. Pediatric Neurology, 2012, 46, 203-211.	1.0	20
151	Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study. Neuro-Oncology, 2012, 14, 1018-1025.	0.6	27
152	Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 2641-2647.	0.8	348
153	Medulloblastoma and primitive neuroectodermal tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 529-548.	1.0	38
154	Pediatric Brain Tumors (An Overview). Pediatric Cancer, 2012, , 61-73.	0.0	0
155	Medulloblastoma/Primitive Neuroectodermal Tumor and Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2012, 26, 881-895.	0.9	5
156	Neurotoxicity of Biologically Targeted Agents in Pediatric Cancer Trials. Pediatric Neurology, 2012, 46, 212-221.	1.0	10
157	Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. Journal of Clinical Oncology, 2012, 30, 2648-2653.	0.8	166
158	Temozolomide for Pediatric High-Grade Gliomas. Current Neurology and Neuroscience Reports, 2012, 12, 111-113.	2.0	1
159	Impact of Molecular Biology Studies on the Understanding of Brain Tumors in Childhood. Current Oncology Reports, 2012, 14, 206-212.	1.8	9
160	Pediatric Brain Tumors and Epilepsy. Seminars in Pediatric Neurology, 2012, 19, 3-8.	1.0	30
161	A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy. Seminars in Pediatric Neurology, 2012, 19, 43-48.	1.0	5
162	Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1. , 2012, , 625-657.		2

#	ARTICLE	IF	CITATIONS
163	Tumors of the Brain and Spine. , 2012, , 1339-1387.		1
164	Center for Neuroscience and Behavioral Medicine: An Innovative Administrative Structure and Possible Paradigm for the Future. <i>Pediatric Neurology</i> , 2011, 44, 1-9.	1.0	1
165	Child Neurology: The Role of the Pediatric Neurologist Both Within and Outside the Academic Setting. <i>Pediatric Neurology</i> , 2011, 44, 10-11.	1.0	4
166	Risk Stratification of Medulloblastoma: A Paradigm for Future Childhood Brain Tumor Management Strategies. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 124-126.	2.0	13
167	Auditory complications in childhood cancer survivors: A report from the childhood cancer survivor study. <i>Pediatric Blood and Cancer</i> , 2011, 57, 126-134.	0.8	48
168	Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Neuro-Oncology</i> , 2011, 13, 298-306.	0.6	76
169	Radiation Therapy for Pediatric Low-Grade Gliomas: Survival and Sequelae. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 10-13.	2.0	8
170	Ocular late effects in childhood and adolescent cancer survivors: A report from the childhood cancer survivor study. <i>Pediatric Blood and Cancer</i> , 2010, 54, 103-109.	0.8	77
171	Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. <i>Neuro-Oncology</i> , 2010, 12, 1173-1186.	0.6	111
172	Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 5, 329-334.	0.8	104
173	Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3069-3075.	0.8	178
174	Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 87-108.	0.9	11
175	A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. <i>European Journal of Cancer</i> , 2010, 46, 3287-3293.	1.3	59
176	Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 946-958.	3.0	450
177	The Childhood Cancer Survivor Study: A National Cancer Instituteâ€œSupported Resource for Outcome and Intervention Research. <i>Journal of Clinical Oncology</i> , 2009, 27, 2308-2318.	0.8	551
178	Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings. <i>Journal of Clinical Oncology</i> , 2009, 27, 2339-2355.	0.8	360
179	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. <i>Clinical Cancer Research</i> , 2009, 15, 5032-5039.	3.2	74
180	Primary spinal cord tumors of childhood: effects of clinical presentation, radiographic features, and pathology on survival. <i>Journal of Neuro-Oncology</i> , 2009, 95, 259-269.	1.4	43

#	ARTICLE	IF	CITATIONS
181	Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 94-96.	2.0	1
182	Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2009, 52, 169-176.	0.8	38
183	Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. <i>Pediatric Blood and Cancer</i> , 2009, 52, 791-795.	0.8	132
184	Neurocognitive status in long-term survivors of childhood CNS malignancies: A report from the Childhood Cancer Survivor Study. <i>Neuropsychology</i> , 2009, 23, 705-717.	1.0	281
185	Reduction of health status 7 years after addition of chemotherapy to cranio-spinal irradiation for medulloblastoma: A follow-up study on PNET-3 trial survivors. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 111-113.	2.0	3
186	The cerebellar mutism syndrome and its relation to cerebellar cognitive function and the cerebellar cognitive affective disorder. <i>Developmental Disabilities Research Reviews</i> , 2008, 14, 221-228.	2.9	109
187	Central Nervous System Tumors. <i>Pediatric Clinics of North America</i> , 2008, 55, 121-145.	0.9	48
188	Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. <i>Neuro-Oncology</i> , 2008, 10, 1040-1060.	0.6	114
189	Childhood Brain Tumors: Accomplishments and Ongoing Challenges. <i>Journal of Child Neurology</i> , 2008, 23, 1122-1127.	0.7	67
190	Management of and Prognosis With Medulloblastoma. <i>Archives of Neurology</i> , 2008, 65, 1419.	4.9	157
191	Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3137-3143.	0.8	67
192	PROGRESS IN THE TREATMENT OF CHILDHOOD BRAIN TUMORS: No Room for Complacency. <i>Pediatric Hematology and Oncology</i> , 2007, 24, 79-84.	0.3	9
193	Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. <i>Pediatric Blood and Cancer</i> , 2007, 48, 278-284.	0.8	43
194	Medulloblastoma in childhood: new biological advances. <i>Lancet Neurology, The</i> , 2007, 6, 1073-1085.	4.9	239
195	Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 129-132.	2.0	15
196	Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 129, 132.	2.0	0
197	Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 130, 132.	2.0	8
198	Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 130-2.	2.0	7

#	ARTICLE	IF	CITATIONS
199	Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4202-4208.	0.8	834
200	New Primary Neoplasms of the Central Nervous System in Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor Study. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1528-1537.	3.0	492
201	Late-Occurring Stroke Among Long-Term Survivors of Childhood Leukemia and Brain Tumors: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 5277-5282.	0.8	337
202	Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. <i>Journal of Neurosurgery: Pediatrics</i> , 2006, 105, 444-451.	0.8	183
203	Is postoperative chemotherapy alone sufficient to treat young children with medulloblastoma?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 386-387.	4.3	2
204	Long-term outcomes of adult survivors of childhood cancer. <i>Cancer</i> , 2005, 104, 2557-2564.	2.0	192
205	Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1281-1287.	2.0	37
206	A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1968-1974.	2.0	45
207	Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma. <i>Cancer</i> , 2005, 104, 2862-2871.	2.0	58
208	New insights into childhood ependymomas. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 107-109.	2.0	5
209	Journal of Neuro-Oncology: Childhood Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2005, 75, 237-237.	1.4	0
210	Progress and Challenges in Childhood Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2005, 75, 239-242.	1.4	28
211	Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. <i>Neurology</i> , 2005, 64, 553-555.	1.5	242
212	Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 7621-7631.	0.8	381
213	Phase I Clinical Trial of Mafosfamide in Infants and Children Aged 3 Years or Younger With Newly Diagnosed Embryonal Tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001). <i>Journal of Clinical Oncology</i> , 2005, 23, 525-531.	0.8	42
214	Current approaches to CNS tumors in infants and very young children. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 681-690.	1.4	10
215	Psychological Outcomes in Long-Term Survivors of Childhood Brain Cancer: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 999-1006.	0.8	346
216	Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. <i>Neuro-Oncology</i> , 2004, 6, 113-118.	0.6	58

#	ARTICLE	IF	CITATIONS
217	Current treatment of medulloblastoma: Recent advances and future challenges. <i>Seminars in Oncology</i> , 2004, 31, 666-675.	0.8	80
218	Preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 127-128.	2.0	0
219	New treatments in pediatric brain tumors. <i>Current Treatment Options in Neurology</i> , 2004, 6, 377-389.	0.7	3
220	Gene expression profiling to analyze embryonal tumors of the central nervous system. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 117-119.	2.0	1
221	Neurocognitive dysfunction in children with neurofibromatosis type 1. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 129-136.	2.0	68
222	Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. <i>Cancer</i> , 2003, 97, 663-673.	2.0	342
223	Medulloblastoma: Present Concepts of Stratification into Risk Groups. <i>Pediatric Neurosurgery</i> , 2003, 39, 60-67.	0.4	145
224	Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors. <i>Oncologist</i> , 2003, 8, 174-186.	1.9	78
225	Long-Term Neurologic and Neurosensory Sequelae in Adult Survivors of a Childhood Brain Tumor: Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 3255-3261.	0.8	298
226	Final Height and Body Mass Index among Adult Survivors of Childhood Brain Cancer: Childhood Cancer Survivor Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4731-4739.	1.8	147
227	Review Article : Intracranial Neoplasms in Children With Neurofibromatosis 1. <i>Journal of Child Neurology</i> , 2002, 17, 630-637.	0.7	71
228	Review Article : Therapy for Plexiform Neurofibromas in Children With Neurofibromatosis 1: An Overview. <i>Journal of Child Neurology</i> , 2002, 17, 638-641.	0.7	32
229	Study design and cohort characteristics of the childhood cancer survivor study: A multi-institutional collaborative project. <i>Medical and Pediatric Oncology</i> , 2002, 38, 229-239.	1.0	632
230	Radiation-induced neurocognitive decline: The risks and benefits of reducing the amount of whole-brain irradiation. <i>Current Neurology and Neuroscience Reports</i> , 2002, 2, 131-133.	2.0	19
231	Growth Hormone Replacement Therapy in Children With Medulloblastoma: Use and Effect on Tumor Control. <i>Journal of Clinical Oncology</i> , 2001, 19, 480-487.	0.8	104
232	Intellectual Outcome After Reduced-Dose Radiation Therapy Plus Adjuvant Chemotherapy for Medulloblastoma: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 3470-3476.	0.8	476
233	Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 275-282.	1.1	37
234	Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. <i>Nature Genetics</i> , 2001, 29, 143-152.	9.4	421

#	ARTICLE	IF	CITATIONS
235	Low-Stage Medulloblastoma: Final Analysis of Trial Comparing Standard-Dose With Reduced-Dose Neuraxis Irradiation. <i>Journal of Clinical Oncology</i> , 2000, 18, 3004-3011.	0.8	275
236	Correlation of Neurosurgical Subspecialization with Outcomes in Children with Malignant Brain Tumors. <i>Neurosurgery</i> , 2000, 47, 879-887.	0.6	123
237	Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. , 2000, 88, 2189-2193.		160
238	Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector producer cells followed by intravenous ganciclovir administration. <i>Journal of Neurosurgery</i> , 2000, 92, 249-254.	0.9	79
239	Chemotherapy: Low-Grade Gliomas of the Hypothalamus and Thalamus. <i>Pediatric Neurosurgery</i> , 2000, 32, 259-263.	0.4	33
240	Intracranial Germ Cell Tumors. <i>Oncologist</i> , 2000, 5, 312-320.	1.9	285
241	Treatment of Children With Medulloblastomas With Reduced-Dose Craniospinal Radiation Therapy and Adjuvant Chemotherapy: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 2127-2127.	0.8	554
242	Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 832-832.	0.8	674
243	Quality of Life of Adult Survivors of Germinomas Treated with Craniospinal Irradiation. <i>Neurosurgery</i> , 1999, 45, 1292-1298.	0.6	63
244	Brain Tumors in Children. <i>Archives of Neurology</i> , 1999, 56, 421.	4.9	91
245	Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children's Cancer Group Study, CCG-9881. <i>Journal of Neuro-Oncology</i> , 1999, 45, 47-54.	1.4	23
246	Alternative treatments for childhood brain tumors. <i>Child's Nervous System</i> , 1999, 15, 789-794.	0.6	7
247	Chemotherapy for low-grade gliomas. <i>Child's Nervous System</i> , 1999, 15, 506-513.	0.6	57
248	Primary central nervous system tumors in children. <i>Current Treatment Options in Neurology</i> , 1999, 1, 395-408.	0.7	24
249	A Multi-Institutional Retrospective Study of Intracranial Ependymoma in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 1999, 21, 203-211.	0.3	173
250	Medulloblastoma. <i>Current Opinion in Neurology</i> , 1999, 12, 681-685.	1.8	20
251	Treatment of diencephalic syndrome with chemotherapy. , 1998, 83, 166-172.		65
252	Comment: Intracranial ependymomas in children. <i>Medical and Pediatric Oncology</i> , 1998, 30, 330-330.	1.0	0

#	ARTICLE	IF	CITATIONS
253	Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. <i>Journal of Neurosurgery</i> , 1998, 88, 695-703.	0.9	303
254	Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group Trial No. CCG-945. <i>Journal of Neurosurgery</i> , 1998, 89, 52-59.	0.9	273
255	Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. <i>Journal of Neurosurgery</i> , 1997, 86, 747-754.	0.9	562
256	Primitive Neuroectodermal Tumors of the Central Nervous System. <i>Brain Pathology</i> , 1997, 7, 765-784.	2.1	97
257	Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the nf1 optic pathway glioma task force. <i>Annals of Neurology</i> , 1997, 41, 143-149.	2.8	434
258	The Effectiveness of Chemotherapy for Childhood Medulloblastoma (&lt;Special Issue&gt;Topics of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	0
259	Results of a Prospective Randomized Trial Comparing Standard Dose Neuraxis Irradiation (3,600 Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.4	130
260	Pediatric Neurosurgery, 1996, 24, 167-177.		
260	Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. <i>Journal of Neurosurgery</i> , 1996, 85, 56-65.	0.9	695
261	Alternative Therapies for Children with Brain Stem Gliomas: Immunotherapy and Gene Therapy. <i>Pediatric Neurosurgery</i> , 1996, 24, 217-222.	0.4	12
262	Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant Î²-interferon and hyperfractionated radiation therapy: A Childrens Cancer Group phase I/II study. , 1996, 77, 2150-2156.		68
263	Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 899-904.	0.4	134
264	An integrated approach to the treatment of chiasmatic-hypothalamic gliomas. <i>Journal of Neuro-Oncology</i> , 1996, 28, 167-83.	1.4	50
265	Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors. <i>Oncologist</i> , 1996, 1, 381-393.	1.9	17
266	Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. <i>Cancer</i> , 1995, 75, 1051-1059.	2.0	234
267	Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. <i>Journal of Neuro-Oncology</i> , 1995, 24, 21-28.	1.4	201
268	Quality of long-term survival in young children with medulloblastoma. <i>Journal of Neurosurgery</i> , 1994, 80, 1004-1010.	0.9	110
269	Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A childrens cancer group phase 1/11 trial. <i>Cancer</i> , 1994, 74, 1827-1834.	2.0	168
270	Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. <i>Journal of Neurosurgery</i> , 1994, 81, 690-698.	0.9	425



#	ARTICLE	IF	CITATIONS
271	Results of a pilot study of low-dose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors. <i>Cancer</i> , 1993, 71, 2647-2652.	2.0	45
272	Early cystic/necrotic changes after hyperfractionated radiation therapy in children with brain stem gliomas data from the childrens cancer group. <i>Cancer</i> , 1993, 71, 2666-2674.	2.0	47
273	Fatal brain stem necrosis after standard posterior fossa radiation and aggressive chemotherapy for metastatic medulloblastoma. <i>Cancer</i> , 1993, 71, 4111-4117.	2.0	15
274	Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas A childrens cancer group phase I/II trial. <i>Cancer</i> , 1993, 72, 1414-1421.	2.0	134
275	Magnetic Resonance Scans Should Replace Biopsies for the Diagnosis of Diffuse Brain Stem Gliomas. <i>Neurosurgery</i> , 1993, 33, 1026-1030.	0.6	185
276	Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. <i>Journal of Neuro-Oncology</i> , 1992, 14, 151-8.	1.4	59
277	Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. <i>Annals of Neurology</i> , 1992, 32, 551-554.	2.8	149
278	Choroid plexus carcinoma of childhood. <i>Cancer</i> , 1992, 69, 580-585.	2.0	147
279	Spinal cord compression in widely metastatic Wilms' tumor. Paraplegia in two children with anaplastic wilms' tumor. <i>Cancer</i> , 1992, 69, 2726-2730.	2.0	16
280	Vascular malformation with radiation vasculopathy after treatment of chiasmatic/hypothalamic glioma. <i>Cancer</i> , 1992, 70, 887-893.	2.0	50
281	The effects of adjuvant chemotherapy on growth in children with medulloblastoma. <i>Cancer</i> , 1992, 70, 2013-2017.	2.0	106
282	Cognitive deficits in long-term survivors of childhood brain tumors. <i>Child's Nervous System</i> , 1991, 7, 2-12.	0.6	144
283	Microphthalmia and chorioretinal lesions in a girl with an Xp22.2-pter deletion and partial 3p trisomy: Clinical observations relevant to aicardi syndrome gene localization. <i>American Journal of Medical Genetics Part A</i> , 1990, 37, 182-186.	2.4	42
284	Hyperfractionated radiotherapy for children with brainstem gliomas: A pilot study using 7,200 cGy. <i>Annals of Neurology</i> , 1990, 27, 167-173.	2.8	78
285	Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. <i>Annals of Neurology</i> , 1990, 28, 823-828.	2.8	85
286	Central nervous system and langerhans' cell histiocytosis. <i>Medical and Pediatric Oncology</i> , 1990, 18, 325-328.	1.0	17
287	Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. <i>Cancer</i> , 1990, 65, 412-417.	2.0	69
288	Monosomy 22 in rhabdoid or atypical tumors of the brain. <i>Journal of Neurosurgery</i> , 1990, 73, 710-714.	0.9	172

#	ARTICLE	IF	CITATIONS
289	Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. <i>Human Pathology</i> , 1990, 21, 245-252.	1.1	60
290	Acute Mental Status Changes in Children With Systemic Cancer. <i>Pediatrics</i> , 1990, 85, 353-360.	1.0	45
291	A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. <i>Journal of Neurosurgery</i> , 1989, 70, 707-713.	0.9	324
292	Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. <i>Genes Chromosomes and Cancer</i> , 1989, 1, 139-147.	1.5	156
293	An animal model to detect the neuropsychological toxicity of anticancer agents. <i>Medical and Pediatric Oncology</i> , 1989, 17, 216-221.	1.0	26
294	Clinical, cytogenetic, and pedigree findings in 18 cases of Aicardi syndrome. <i>American Journal of Medical Genetics Part A</i> , 1989, 32, 461-467.	2.4	113
295	Suprasellar germinomas in childhood. A reappraisal. <i>Cancer</i> , 1989, 63, 340-344.	2.0	68
296	Neurologic complications in children with soft tissue and osseous sarcoma. <i>Cancer</i> , 1989, 64, 2600-2603.	2.0	34
297	Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: A preliminary report. <i>Annals of Neurology</i> , 1988, 24, 503-508.	2.8	85
298	Results of the treatment of children with recurrent gliomas with lomustine and vincristine. <i>Cancer</i> , 1988, 61, 896-902.	2.0	55
299	Late recurrence of primitive neuroectodermal Tumor/Medulloblastoma. <i>Cancer</i> , 1988, 62, 826-830.	2.0	40
300	Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: An update. <i>Annals of Neurology</i> , 1988, 23, 79-85.	2.8	260
301	Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. <i>Journal of Neurosurgery</i> , 1987, 67, 65-70.	0.9	202
302	Cerebellar sclerosis in pediatric cancer patients. <i>Journal of Neuro-Oncology</i> , 1987, 4, 353-60.	1.4	12
303	Long-term sequelae of cancer treatment on the central nervous system in childhood. <i>Medical and Pediatric Oncology</i> , 1987, 15, 241-253.	1.0	212
304	Pineocytomas of childhood a reappraisal of natural history and response to therapy. <i>Cancer</i> , 1987, 59, 1353-1357.	2.0	72
305	Magnetic resonance imaging in the evaluation of treatment-related central nervous system damage. <i>Cancer</i> , 1986, 58, 635-640.	2.0	118
306	Incidence, Presentation, and Outcome of Spinal Cord Disease in Children With Systemic Cancer. <i>Pediatrics</i> , 1986, 78, 438-443.	1.0	94

#	ARTICLE	IF	CITATIONS
307	Leptomeningeal dissemination of primary central nervous system tumors of childhood. <i>Annals of Neurology</i> , 1985, 18, 217-221.	2.8	127
308	Oligodendroglioma of the posterior fossa in childhood. <i>Cancer</i> , 1985, 56, 195-199.	2.0	49
309	Magnetic resonance imaging in the evaluation of intracranial tumors of childhood. <i>Cancer</i> , 1985, 56, 1767-1772.	2.0	16
310	Management of Children with Primitive Neuroectodermal Tumors of the Posterior Fossa/Medulloblastoma. <i>Pediatric Neurosurgery</i> , 1985, 12, 272-282.	0.4	53
311	Intracranial embryonal cell carcinoma. <i>Cancer</i> , 1984, 54, 520-524.	2.0	45
312	High dose systemic methotrexate-associated acute neurologic dysfunction. <i>Medical and Pediatric Oncology</i> , 1983, 11, 159-161.	1.0	54
313	Cerebral Gangliogliomas during Childhood. <i>Neurosurgery</i> , 1983, 13, 124-128.	0.6	131
314	Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. <i>Oncotarget</i> , 0, 7, 42837-42842.	0.8	7